klinische Phase I Studie: bispezifische Antikörper gegen minimale Resterkrankung AML

Patients interested in participating in the study described here can contact the University Hospital of Tübingen at this email address: [email protected] Please note the inclusion and exclusion criteria! Ideally, please bring a doctor's letter and your previous treatment results. Here are the details of the study: We interviewed Professor Salih from the University Hospital of Tübingen. He explained a new phase 1 study on the treatment of minimal residual disease after successful standard therapy for acute myeloid leukemia (AML) with bispecific antibodies. Background to the study: Standard therapy for AML consists of intensive chemotherapy, which often cannot eliminate all leukemia cells, which is why the risk of relapse is high. The leukemia cells that remain in the body after successful therapy are referred to as "minimal residual disease" (MRD). Aim of the study: The goal is to eliminate this minimal residual disease. Bispecific antibodies are designed to activate T cells to specifically destroy remaining leukemia cells. How bispecific antibodies work: These antibodies are designed to bind to both the leukemia cells and the T cells. This causes T cells to recognize and destroy the leukemia cells. The major advantage is that these antibodies act in a targeted manner and largely spare healthy cells. Study procedure and duration: The primary goal of the Phase 1 study is to determine the safe dose and tolerability of the antibody. The study begins with a low dose of the antibody, administered weekly for 12 weeks. Regular monitoring ensures that the therapy is effective and safe. Inclusion and exclusion criteria: Inclusion: Adult patients with AML who are in remission but still have minimal residual disease. Exclusion: Patients must not be too ill to tolerate the therapy. Side effects and risks: Potential side effects include flu-like symptoms such as fever and chills. However, these side effects are usually short-term and easily treatable. Please note: This is a collaboration between the University Hospital of Tübingen and the Strube Foundation. Neither receives any financial benefit from this. 0:00 Intro 0:26 Target group of the study 2:25 Problem of minimal residual disease 5:11 Modern cancer therapies: chemotherapy vs. immunotherapy 5:45 Bispecific antibodies 13:51 Why does chemotherapy have to be done first? 15:53 ​​Benefits of bispecific antibody therapy 18:20 Possible side effects 21:17 Treatment procedure and duration 22:11 Mechanism of action and administration frequency 24:40 The Phase I study 27:14 Patient participation criteria 29:42 Study procedure 33:51 Patient participation and safety in clinical trials 37:13 Contact options for interested participants